Selected Drugs Clear All
MultiCheck Results
- 33
Interactions
Avoid/Use Alternative |
||
|
Frova
(frovatriptan) + oxymorphone
(generic) |
||
Avoid/Use Alternativefrovatriptan + oxymorphone use alternative or monitor resp. rate, serotonin syndrome sx, especially during initiation/titration; decr. oxymorphone start dose by at least 50%, consider decr. frovatriptan dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, serotonin syndrome (additive effects) |
||
|
Frova
(frovatriptan) + sodium oxybate
(generic) |
||
Avoid/Use Alternativefrovatriptan + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
Levsin
(hyoscyamine) + sodium oxybate
(generic) |
||
Avoid/Use Alternativehyoscyamine + oxybate use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
|
oxymorphone
(generic) + sodium oxybate
(generic) |
||
Avoid/Use Alternativeoxymorphone + oxybate use alternative or monitor resp. rate; consider holding oxybate, especially if peri- or post-operative opioid analgesia required: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects) |
||
Monitor/Modify Tx |
||
|
Emgality (galcanezumab-gnlm)
(galcanezumab) + Frova
(frovatriptan) |
||
Monitor/Modify Txgalcanezumab + frovatriptan monitor BP: combo may incr. risk of HTN (additive effects) |
||
|
Emgality (galcanezumab-gnlm)
(galcanezumab) + Maxzide
(triamterene/ hydrochlorothiazide) |
||
Monitor/Modify Txgalcanezumab + hydrochlorothiazide monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) galcanezumab + triamterene monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Emgality (galcanezumab-gnlm)
(galcanezumab) + verapamil
(generic) |
||
Monitor/Modify Txgalcanezumab + verapamil monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
ferrous sulfate
(generic) + Levsin
(hyoscyamine) |
||
Monitor/Modify Txferrous sulfate + hyoscyamine separate admin. by 1h: combo may decr. hyoscyamine levels, efficacy (absorption decreased via chelation) |
||
|
Frova
(frovatriptan) + lakritze
(licorice (Glycyrrhiza glabra)) |
||
Monitor/Modify Txfrovatriptan + licorice monitor BP w/ large amounts of licorice: combo may incr. risk of HTN (additive effects) |
||
|
Frova
(frovatriptan) + Maxzide
(triamterene/ hydrochlorothiazide) |
||
Monitor/Modify Txfrovatriptan + hydrochlorothiazide monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) frovatriptan + triamterene monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Frova
(frovatriptan) + verapamil
(generic) |
||
Monitor/Modify Txfrovatriptan + verapamil monitor BP: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
lakritze
(licorice (Glycyrrhiza glabra)) + Maxzide
(triamterene/ hydrochlorothiazide) |
||
Monitor/Modify Txlicorice + hydrochlorothiazide monitor BP, potassium w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy; may incr. risk of hypokalemia (antagonistic effects; additive effects) licorice + triamterene monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
lakritze
(licorice (Glycyrrhiza glabra)) + verapamil
(generic) |
||
Monitor/Modify Txlicorice + verapamil monitor BP w/ large amounts of licorice: combo may decr. antihypertensive agent efficacy (antagonistic effects) |
||
|
Levsin
(hyoscyamine) + oxymorphone
(generic) |
||
Monitor/Modify Txhyoscyamine + oxymorphone monitor resp. rate; decr. oxymorphone start dose by at least 50%, consider decr. hyoscyamine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe constipation, paralytic ileus, urinary retention (additive effects) |
||
|
Maxzide
(triamterene/ hydrochlorothiazide) + oxymorphone
(generic) |
||
Monitor/Modify Txhydrochlorothiazide + oxymorphone monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope; may decr. hydrochlorothiazide efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release) triamterene + oxymorphone monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope; may decr. triamterene efficacy (additive effects; antagonistic effects, opioids may induce antidiuretic hormone release) |
||
|
Maxzide
(triamterene/ hydrochlorothiazide) + RhoGAM
(Rho(D) immune globulin) |
||
Monitor/Modify Txhydrochlorothiazide + Rho(D) immune globulin monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects) triamterene + Rho(D) immune globulin monitor renal fxn; use lowest Rho(D) immune globulin infusion rate possible: combo may incr. risk of nephrotoxicity (additive effects) |
||
|
Maxzide
(triamterene/ hydrochlorothiazide) + Urecholine
(bethanechol) |
||
Monitor/Modify Txhydrochlorothiazide + bethanechol monitor BP: combo may incr. risk of hypotension (additive effects) triamterene + bethanechol monitor BP: combo may incr. risk of hypotension (additive effects) |
||
|
oxymorphone
(generic) + Urecholine
(bethanechol) |
||
Monitor/Modify Txoxymorphone + bethanechol monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects) |
||
|
oxymorphone
(generic) + verapamil
(generic) |
||
Monitor/Modify Txoxymorphone + verapamil monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects) |
||
|
Urecholine
(bethanechol) + verapamil
(generic) |
||
Monitor/Modify Txbethanechol + verapamil monitor BP: combo may incr. risk of hypotension (additive effects) |
||
Caution Advised |
||
|
Frova
(frovatriptan) + Levsin
(hyoscyamine) |
||
Caution Advisedfrovatriptan + hyoscyamine caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects) |
||
|
ginseng, Asian (Panax ginseng)
(common name) + verapamil
(generic) |
||
Caution Advisedginseng, Asian + verapamil caution advised: combo may decr. verapamil levels, efficacy (hepatic metab. induced) |
||
|
lamivudine
(generic) + Maxzide
(triamterene/ hydrochlorothiazide) |
||
Caution Advisedlamivudine + triamterene caution advised: combo may incr. lamivudine levels, risk of adverse effects (renal transport inhibited) |
||
|
lamivudine
(generic) + verapamil
(generic) |
||
Caution Advisedlamivudine + verapamil caution advised: combo may incr. lamivudine levels, risk of adverse effects (renal transport inhibited) |
||
|
Levsin
(hyoscyamine) + Maxzide
(triamterene/ hydrochlorothiazide) |
||
Caution Advisedhyoscyamine + hydrochlorothiazide caution advised: combo may incr. hydrochlorothiazide levels, risk of adverse effects (absorption increased) |
||
|
Levsin
(hyoscyamine) + Urecholine
(bethanechol) |
||
Caution Advisedhyoscyamine + bethanechol caution advised: combo may decr. efficacy of both drugs (antagonistic effects) |
||
Additional Considerations |
||
|
oxymorphone
|
||
|
consider prescribing an opioid overdose reversal agent, especially w/ concomitant CNS depressant use add MAO inhibitor to Interaction Check if recent (14 days) use avoid combo with beverages or products containing ethanol and some oxymorphone extended-release (ER) tablets; combo may incr. oxymorphone release rate, levels, risk of adverse effects, incl. life-threatening overdose, decr. duration of efficacy |
||
|
hyoscyamine
in Levsin
|
||
|
caution advised w/ concurrent oral drugs requiring rapid onset; hyoscyamine delays gastric emptying, may alter absorption of concomitant oral drugs |
||
|
lamivudine
|
||
|
avoid combo of lamivudine oral solution w/ oral products containing sorbitol; may give lamivudine tab formulation or monitor virologic response more frequently if combo cannot be avoided; sorbitol may decr. bioavailability of lamivudine, resulting in decr. levels, efficacy |
||